−0.6538USD
−22.46 MUSD
9.95 M
About MiNK Therapeutics, Inc.
Sector
Industry
CEO
Jennifer S. Buell
Website
Headquarters
New York
Employees (FY)
31
Founded
2017
ISIN
US6036931029
FIGI
BBG012J84VS3
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of INKT is 0.9000 USD — it has increased by 3.25% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange MiNK Therapeutics, Inc. stocks are traded under the ticker INKT.
MiNK Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
INKT stock is 3.39% volatile and has beta coefficient of 1.60. Check out the list of the most volatile stocks — is MiNK Therapeutics, Inc. there?
One year price forecast for MiNK Therapeutics, Inc. has a max estimate of 9.0000 USD and a min estimate of 8.0000 USD.
INKT earnings for the last quarter are −0.15 USD per share, whereas the estimation was −0.18 USD resulting in a 17.39% surprise. The estimated earnings for the next quarter are −0.15 USD per share. See more details about MiNK Therapeutics, Inc. earnings.
Yes, you can track MiNK Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
INKT stock has fallen by 10.89% compared to the previous week, the month change is a 1.35% rise, over the last year MiNK Therapeutics, Inc. has showed a 56.31% decrease.
INKT net income for the last quarter is −5.46 M USD, while the quarter before that showed −5.12 M USD of net income which accounts for −6.70% change. Track more MiNK Therapeutics, Inc. financial stats to get the full picture.
Today MiNK Therapeutics, Inc. has the market capitalization of 30.25 M, it has increased by 40.43% over the last week.
No, INKT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, INKT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MiNK Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 31.00 employees. See our rating of the largest employees — is MiNK Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MiNK Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MiNK Therapeutics, Inc. stock shows the sell signal. See more of MiNK Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MiNK Therapeutics, Inc. future price: according to them, INKT price has a max estimate of 9.00 USD and a min estimate of 8.00 USD. Read a more detailed MiNK Therapeutics, Inc. forecast: see what analysts think of MiNK Therapeutics, Inc. and suggest that you do with its stocks.